- Home
- TPST vs COEP Comparison
TPST vs COEP Comparison
Compare TPST & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- COEP
- Stock Information
- Founded
- TPST 2011
- COEP 2017
- Country
- TPST United States
- COEP United States
- Employees
- TPST N/A
- COEP N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TPST Health Care
- COEP Health Care
- Exchange
- TPST Nasdaq
- COEP Nasdaq
- Market Cap
- TPST 33.0M
- COEP 27.4M
- IPO Year
- TPST N/A
- COEP N/A
- Fundamental
- Price
- TPST $7.72
- COEP $10.77
- Analyst Decision
- TPST Hold
- COEP
- Analyst Count
- TPST 3
- COEP 0
- Target Price
- TPST $30.00
- COEP N/A
- AVG Volume (30 Days)
- TPST 94.5K
- COEP 56.9K
- Earning Date
- TPST 08-07-2025
- COEP 08-15-2025
- Dividend Yield
- TPST N/A
- COEP N/A
- EPS Growth
- TPST N/A
- COEP N/A
- EPS
- TPST N/A
- COEP N/A
- Revenue
- TPST N/A
- COEP $62,874.00
- Revenue This Year
- TPST N/A
- COEP N/A
- Revenue Next Year
- TPST N/A
- COEP N/A
- P/E Ratio
- TPST N/A
- COEP N/A
- Revenue Growth
- TPST N/A
- COEP N/A
- 52 Week Low
- TPST $5.35
- COEP $2.31
- 52 Week High
- TPST $28.34
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- TPST 59.30
- COEP 59.53
- Support Level
- TPST $7.13
- COEP $11.30
- Resistance Level
- TPST $8.75
- COEP $12.71
- Average True Range (ATR)
- TPST 0.45
- COEP 0.89
- MACD
- TPST 0.13
- COEP 0.18
- Stochastic Oscillator
- TPST 63.83
- COEP 54.39
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.